AFINITOR

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug AFINITOR contains one active pharmaceutical ingredient (API):

1 Everolimus UNII 9HW64Q8G6G - EVEROLIMUS

Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity of which is known to be upregulated in a number of human cancers. Read about Everolimus

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AFINITOR Tablet	Health Products Regulatory Authority (ZA)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EG02	Everolimus	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
Discover more medicines within L01EG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10131F, 10132G, 10133H, 10135K, 11254H, 11257L, 11258M, 11262R, 11267B, 11362B, 11377T, 11591C, 11592D, 11598K, 11599L, 11607X, 11608Y, 2818H, 2819J, 2985D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 526530901116312, 526530902112310, 526530903119319
Country: CA	Health Products and Food Branch	Identifier(s): 02339501, 02339528, 02369257, 02425645, 02425653, 02425661
Country: EE	Ravimiamet	Identifier(s): 1433281, 1433304, 1433315, 1433337, 1471373, 1471384, 1617229, 1617241
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 09538001, 09538004
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 044580, 044591, 548899
Country: FR	Base de données publique des médicaments	Identifier(s): 62142469, 64201368, 69867865
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 160557, 160562, 241043, 392269, 392271
Country: HK	Department of Health Drug Office	Identifier(s): 59060, 59061, 61710, 63764, 63765, 63766
Country: IE	Health Products Regulatory Authority	Identifier(s): 88009, 88304, 88305
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6512, 6513, 6901
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291023F1020, 4291023F2027, 4291023X1026, 4291023X2022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1050728, 1050730, 1050731, 1050733, 1070279, 1070280, 1070281, 1070282
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 028M2010
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 100471, 92568, 92576
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13653, 13654, 14805
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100211716, 100211722, 100295200
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64504001, W64504002, W64504003, W64505001, W64505002, W64505003
Country: SG	Health Sciences Authority	Identifier(s): 13749P, 13750P, 14130P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 10283341H, 10283342H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699504011456, 8699504011463, 8699504011470, 8699504011487, 8699504011494, 8699504011500
Country: US	FDA, National Drug Code	Identifier(s): 0078-0566, 0078-0567, 0078-0594, 0078-0620, 0078-0626, 0078-0627, 0078-0628
Country: ZA	Health Products Regulatory Authority	Identifier(s): 43/34/1010, 43/34/1133